OCX ready to rebound? OCX Closed up 7% today i
Post# of 10464
(Total Views: 178)
Posted On: 04/02/2018 7:43:11 PM
OCX ready to rebound?
OCX Closed up 7% today in a blood red market, which landed it as the 3rd higest percenage gainer on AMEX, see link, with plenty more room to run.
http://www.investcom.com/us/mpgamex.htm
OCX has been heavily pushed down form over 6 Dollers 3 Months ago to $1.10 last week, the day before the recent $10 mill placement at $1.26 with two existing shareholders. The stock made a violent move the day after (Thursday last week, and continued up today with much higher then average volume, this looks like it could be a short squezze underway.
The company has 39.3 mill shares OS including the 8 mill shares from this recent palcement, these are however restricted, which leaves the amount of tradable shares at 31.3 mill not including any insiders.
The company currently have about $15 mil in cash and a burn rate of $1.1 mil a month, so they have plenty of cash available to get their products into the market, which is expected to happen before the end of 2018, this was reconfirmed on their Fourth Quarter Video cast too, see link below.
http://investors.oncocyte.com/events-and-presentations
See also their presentation from Dec 2017, which is really good.
The company's products are a lung, bladder and breast cancer test kit, which currently test with up to a 92% accuratecy, not including the recent added patented bio makers which will make them even more accurate by the company's own estimate (also mentioned in todays CC)
The company will focus on bringing the lung cancer test kit to market first, as this market by the companys estimate is worth up to $4 bill. Furthermore most lung cancer patients currently need a biopzy in order to detect cancer, which is both expensive and carries significant risk, as such most lung cancer patient only gets it detected in stage 3 or 4, which limits the possibilities of any treatment significantly
They have some outstanding directors on the board and are well positioned for success.
This company trades 38k shares on average (200 day) any whiff of volume and the stock could easily explode up towards the $6 it came from 3 months ago
I bought it today after following it for some time at $2.10, I am obviously biased, so do your own DD
OCX Closed up 7% today in a blood red market, which landed it as the 3rd higest percenage gainer on AMEX, see link, with plenty more room to run.
http://www.investcom.com/us/mpgamex.htm
OCX has been heavily pushed down form over 6 Dollers 3 Months ago to $1.10 last week, the day before the recent $10 mill placement at $1.26 with two existing shareholders. The stock made a violent move the day after (Thursday last week, and continued up today with much higher then average volume, this looks like it could be a short squezze underway.
The company has 39.3 mill shares OS including the 8 mill shares from this recent palcement, these are however restricted, which leaves the amount of tradable shares at 31.3 mill not including any insiders.
The company currently have about $15 mil in cash and a burn rate of $1.1 mil a month, so they have plenty of cash available to get their products into the market, which is expected to happen before the end of 2018, this was reconfirmed on their Fourth Quarter Video cast too, see link below.
http://investors.oncocyte.com/events-and-presentations
See also their presentation from Dec 2017, which is really good.
The company's products are a lung, bladder and breast cancer test kit, which currently test with up to a 92% accuratecy, not including the recent added patented bio makers which will make them even more accurate by the company's own estimate (also mentioned in todays CC)
The company will focus on bringing the lung cancer test kit to market first, as this market by the companys estimate is worth up to $4 bill. Furthermore most lung cancer patients currently need a biopzy in order to detect cancer, which is both expensive and carries significant risk, as such most lung cancer patient only gets it detected in stage 3 or 4, which limits the possibilities of any treatment significantly
They have some outstanding directors on the board and are well positioned for success.
This company trades 38k shares on average (200 day) any whiff of volume and the stock could easily explode up towards the $6 it came from 3 months ago
I bought it today after following it for some time at $2.10, I am obviously biased, so do your own DD
(0)
(0)